Long‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and <scp>MAIC</scp>

Compared with other approved biologics, bimekizumab showed favourable efficacy across the majority of outcomes assessed at Week 48-52, indicating its potential as a durable long-term therapeutic option for patients with moderate-to-severe HS.